June 11, 2008

Skinvisible Appoints New Vice President of Business Development & Marketing

Strategic Plan for Invisicare Strengthens

LAS VEGAS, Nevada. June 11th, 2008 Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that brings unique therapeutic and marketing benefits to topically applied products, announces a new executive appointment. Doreen McMorran will serve as Vice President of Business Development and Marketing, performing an integral role as the Company continues to grow in terms of new licensees, new products, new alliances as well as expansion into areas outside of dermatology. Ms. McMorran will focus on driving business growth through new licensee acquisition for Skinvisible's formulated products and technology. She will contribute to the on-going strategic direction of the Company and will be charged with identifying and growing the Company's business opportunities. The goal is to identify new revenue streams through the penetration of markets complementary and additional to the Company's prime market of dermatology and to enhance the global reach of the Company.

"We have expanded our sales and marketing efforts in order to maintain our strategic business development momentum on a global scale," stated Mr. Terry Howlett, President and CEO of Skinvisible. "With Ms. McMorran's contacts in the dermatology industry and having her drive our strategic sales and marketing efforts, we are confident that she will successfully lead a focused and strategic sales effort that meets our long term growth objectives. We are excited to have Ms. McMorran on board as we continue to position Invisicare as the #1 choice for companies seeking enhanced features for their products and critical product life cycle management."

Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last six years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few, providing medical education for physicians and consumers about dermatology conditions, products and treatments. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

About Invisicare®

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare®. Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare® to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: www.skinvisible.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Press Release Index

Click here to join our mailing list.